Skip to main content

Advertisement

SpringerLink
Log in

A phase II experience evaluating quality of life and survival in linac-based SBRT for prostate cancer

  • Original Research
  • Published:
Journal of Radiation Oncology

An Erratum to this article was published on 27 September 2016

Abstract

Objective

This study aims to evaluate SBRT with volumetric modulated arc therapy (VMAT) and toxicity using five validated quality of life (QOL) instruments.

Methods

An approved prospective NCI-designated phase II study (NCT01581749) was conducted. The inclusion criteria are the following: histologically proven prostate adenocarcinoma, Gleason score 6–7, clinical stage T1b-T2b, PSA ≤20 ng/ml, prostate volume ≤100 cm3, and no prior prostate radiotherapy. SBRT was delivered as 36.25 Gy in five fractions to PTV via VMAT. Patients self-reported on validated QOL measures including the American Urological Association (AUA) Index, Sexual Health Inventory for Men (SHIM), Utilization of Sexual Medications/Devices (USMD), and Expanded Prostate Cancer Index Composite Short Form (EPIC-26). In addition, PSA response and survival were evaluated.

Results

A total of 33 patients were entered into the study. Median time from treatment to last follow up was 30 months. Mean age was 67.5 years. Mean PSA was 6.1 and Gleason scores ranged from 6 to 7. Mean PSA declined by 42 % was observed at 1 month post-treatment and continued to decrease. Three patients (9.7 %) had PSA bounce, with one patient having disease progression (3.0 %). There were no transient side effects or sequelae noted on their QOL questionnaires over the follow-up period of 36 months. Some adverse effects to sexual health were noticed with the majority of these incidences occurring within 1 month after treatment and resolved within 3 months of symptom onset.

Conclusion

SBRT with VMAT for low-intermediate risk prostate cancer is well tolerated. Acute toxicities showed no apparent impact on patient general sense of well-being. No adverse effects were observed over the 36 month period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Thames Jr HD, Witheres HR, Peters, et. al. (1982) Changes in early and late radiation responses with altered dose fractionation: Implications for dose survival relationships. Int J Radiat Biol Phys 8:219.

  2. Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021

    Article  CAS  PubMed  Google Scholar 

  3. Finkelstein SE, Timmerman R, McBride WH, et al. (2011) The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 4(39):752

    Google Scholar 

  4. Truman JP, Garcia-Barros M, Kaag M (2010) Endothelial membrane remodeling is obligate for anti-neogenic radiosenitization during tumor radiosurgery. PLoS One 5:e12310

    Article  PubMed  PubMed Central  Google Scholar 

  5. Garcia-Barros M, Paris F, Cardon-Cardo C, et al. (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:115

    Article  Google Scholar 

  6. King CR, Brooks JD, Gill H, et al. (2012) Long term outcomes from a prospective trial of stereotactic body radiotherapy for low risk prostate cancer. Int J Radiat Oncol Biol Phys 82:877

    Article  PubMed  Google Scholar 

  7. Chen LN, Suy S, Uhm S, et al. (2013) Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol 8:58

    Article  PubMed  PubMed Central  Google Scholar 

  8. McBride SM, Wong DS, Dombrowski JJ, et al. (2012) Hypofractionated stereotactic body radiotherapy in low risk prostate adenocarcinoma: Preliminary results of a multiinstitutional phase I feasibility trial. Cancer 118:3681

    Article  PubMed  Google Scholar 

  9. Bolzicco G, Favretto MS, Satariano N (2013) A single center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 13(1):49

    Article  PubMed  PubMed Central  Google Scholar 

  10. Freeman D, King C (2011) Stereotactic body radiotherapy for low risk prostate cancer: five year outcomes. Radiat Oncol 6:3

    Article  PubMed  PubMed Central  Google Scholar 

  11. Oliai C, Lanciano R, Sprandio B, et al. (2013) Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. Radiat Oncol 2:63–70

    Article  CAS  Google Scholar 

  12. Mantz C, Fernandez E, Zucker I, et al. (2009) A phase II trial of Varian Trilogy based SBRT for low risk prostate cancer: Report of early toxicity and disease control outcomes. Int J Radiat Oncol Biol Phys 75:s326

    Article  Google Scholar 

  13. Boike T, Lotan Y, Cho LC, et al. (2011) Phase I dose escalation study of stereotactic body radiotherapy for low and intermediate risk prostate cancer. J Clin Oncolgy 29:2020

    Article  Google Scholar 

  14. Madsen BL, His RA, Pham HT, et al. (2007) Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP) 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys 67:1099

  15. Alongi F, Cozzi L, Arcangeli S, et al. (2013) Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol 8:171

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kirkpatrick JP, Meyer JJ, Marks LB (2008) The linear quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 18:240

    Article  PubMed  Google Scholar 

  17. Kupelian P, Mehta N, King C, et al. (2015) Stereotactic body radiation therapy for prostate cancer: rational and reasonable. Pract Radiat Oncol 5:188–192

    Article  PubMed  Google Scholar 

  18. Damico AV, Whittington R, Malkowitz SB, et al. (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95:281–286

    Article  Google Scholar 

  19. Aizer AA, YU JB, Colberg JW (2009) Radical prostatectomy vs intensity modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol 93:185–191

    Article  PubMed  Google Scholar 

  20. American Society of Radiation Oncology, Practice Management, (2014) SBRT model policy. Available at: https://wwwastroorg/uploadedfiles/ Main_Site/Practice/Management/reimbursement/2013Hpcoding%20guidelines_SBRT_Final Assessed September.

  21. Yu J, Sandler H (2015) Stereotactic body radiation therapy: let’s not give up on progress. Pract Radiat Oncol 5:193–196

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Lankenau Medical Center Main Line Health, Wynnewood, PA, 19096, USA

    Albert DeNittis, Abimbola Orisamolu, Saritha Ravella, David Gasalberti & David Wang

  2. Lankenau Institute for Medical Research, Wynnewood, PA, 19096, USA

    Albert DeNittis

  3. Department of Medical Oncology, Lankenau Medical Center, Wynnewood, PA, 19096, USA

    Yue Wang

Authors
  1. Albert DeNittis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yue Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abimbola Orisamolu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Saritha Ravella
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Gasalberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert DeNittis.

Ethics declarations

Conflicts of interest

Albert DeNittis has no conflict of interest and no funding or support was received. Yue Wang has no conflict of interest and no funding or support was received. Abimbola Orisamola has no conflict of interest and no funding or support was received. Saritha Ravella has no conflict of interest and no funding or support was received. David Gasalberti has no conflict of interest and no funding or support was received. David Wang has no conflict of interest and no funding or support was received.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional/national research committee and with the 1964 Helsinki Declaration and its later amendments or compatible ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s13566-016-0259-2.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

DeNittis, A., Wang, Y., Orisamolu, A. et al. A phase II experience evaluating quality of life and survival in linac-based SBRT for prostate cancer. J Radiat Oncol 5, 445–451 (2016). https://doi.org/10.1007/s13566-016-0249-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13566-016-0249-4

Keywords

Search

Navigation